<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0123-9392</journal-id>
<journal-title><![CDATA[Infectio]]></journal-title>
<abbrev-journal-title><![CDATA[Infect.]]></abbrev-journal-title>
<issn>0123-9392</issn>
<publisher>
<publisher-name><![CDATA[Asociación Colombiana de Infectología.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0123-93922017000400208</article-id>
<article-id pub-id-type="doi">10.22354/in.v21i4.683</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Trastornos de la densidad mineral ósea en personas con VIH en tratamiento antirretroviral Pereira-Risaralda-Colombia]]></article-title>
<article-title xml:lang="en"><![CDATA[Disorders of bone mineral density in patients with HIV on antiretroviral treatment-Colombia Risaralda Pereira]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ruiz-Henao]]></surname>
<given-names><![CDATA[Gloria I.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Arenas-Quintero]]></surname>
<given-names><![CDATA[Henry Mauricio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Estrada-Álvarez]]></surname>
<given-names><![CDATA[Jorge M.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Villegas-Muñoz]]></surname>
<given-names><![CDATA[Yuledy]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Clínica Comfamiliar Programa VIH Contacto Grupo de Investigación Salud Comfamiliar]]></institution>
<addr-line><![CDATA[Pereira Risaralda]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2017</year>
</pub-date>
<volume>21</volume>
<numero>4</numero>
<fpage>208</fpage>
<lpage>213</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0123-93922017000400208&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0123-93922017000400208&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0123-93922017000400208&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo:  La osteoporosis es común en las personas con el virus de inmunodeficiencia humana (VIH). La etiología es multifactorial, involucrando factores de riesgo tradicionales, efectos directos de la infección por el VIH y efectos de los medicamentos antiretrovirales (ARV). Las nuevas evidencias sugieren que el aumento de la prevalencia de la osteoporosis en las personas infectadas por el VIH se traduce en un mayor riesgo de fractura que puede conducir al aumento de morbilidad y mortalidad.  Materiales y métodos:  Se realizó un estudio descriptivo de corte transversal en 180 pacientes, que permitió conocer los trastornos de baja masa ósea que presentaban los pacientes estudiados que recibían terapia ARV. Para la medición se usó el método DXA (Dual Energy X Ray Absorptiometry) de columna lumbar y cuello femoral y para la clasificación los criterios de la OMS .  Resultados:  Se evaluaron 180 pacientes, 76,5% fueron hombres, con un promedio de edad de 41± 11,27 años. Resultaron normales 72,6%, Osteopenia 20,6% y osteoporosis en el 20,6% y osteoporosis en el 6,7%. El análisis multivariado mostró una asociación significativa importante de la Nevirapina frente a la disminución de la masa ósea (OR 0,10 IC95% 0,01 - 0,8). La combinación Tenofovir / Emtricitabina mostró una frecuencia más alta entre pacientes con disminución de la masa ósea (ORa 3.664 IC95% 1.2 - 11.0) .  Conclusiones:  Se hace necesario realizar tamizaje DXA a los pacientes que reciben TAR, para realizar un diagnóstico y tratamiento temprano y evitar complicaciones óseas que alteren la calidad de vida de las personas con VIH.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective:  Osteoporosis is common in people with human immunodeficiency virus (HIV). The etiology is multifactorial, involving traditional risk factors, direct effects of HIV infection and effects of antiretroviral drugs (ARVs). New evidence suggests that the increased prevalence of osteoporosis in people with HIV results in an increased risk of fracture that can lead to increased morbidity and mortality.  Materials and Methods:  A descriptive cross-sectional study was undertaken of 180 patients, which allowed us to see the low bone mass disorders in patients of the study who were receiving ARV therapy. Measurements of lumber spine and femoral neck were made using the DXA (Dual Energy X-Ray Absorptiometry) method and for the classification, criteria of the WHO were used.  Results:  180 patients were evaluated. 76.5% were men, with an average age of 41 +-11.27 years. 72.6% were normal, 20.6% had osteopenia and 6.7% osteoporosis. The multivariate analysis showed an important significant association of Nevirapine with the decreased bone mass (ORa 0.10 IC95% 0.01 - 0.8). The combination of Tenofovir / Emtricitabine showed a higher frequency among patients with low bone mass (ORa 3,664 IC95% 1.2 - 11.0).  Conclusions:  DXA screening is necessary for patients receiving TAR, in order to make a diagnosis, give early treatment and prevent bone complications that affect the quality of life of people with HIV.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[VIH]]></kwd>
<kwd lng="es"><![CDATA[Terapia Antiretroviral]]></kwd>
<kwd lng="es"><![CDATA[Densidad Osea.]]></kwd>
<kwd lng="en"><![CDATA[HIV]]></kwd>
<kwd lng="en"><![CDATA[Antiretroviral therapy]]></kwd>
<kwd lng="en"><![CDATA[Bone density.]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Osteoporosis. Definición. Epidemiología]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muñoz-Torres]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Varsavsky M]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Osteopororos Metab Min]]></source>
<year>2010</year>
<volume>2</volume>
<numero>^s3</numero>
<issue>^s3</issue>
<supplement>3</supplement>
<page-range>7-9</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Epidemiología de la osteoporosis Epidemiology of osteoporosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gonz]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Mar]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Molina]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Colomb Reumatol]]></source>
<year>2009</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>61-75</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Epidemiology of osteoporosis in Latin America 2008]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Riera-Espinoza]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[Salud Publica Mex]]></source>
<year>2009</year>
<volume>51</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>2001-4</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Osteoporosis y factores de riesgo en una población masculina latinoamericana]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jj]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Navarro]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Rf]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Colomb Reumatol]]></source>
<year>2007</year>
<volume>14</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>99-105</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Bone Loss in the HIV-Infected Patient : Evidence, Clinical Implications , and Treatment Strategies]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[VW]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[TT]]></given-names>
</name>
</person-group>
<source><![CDATA[J Infect Dis]]></source>
<year>2012</year>
<volume>205</volume>
<numero>^s3</numero>
<issue>^s3</issue>
<supplement>3</supplement>
<page-range>391-8</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Osteoporosis and bone health in HIV]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Powderly]]></surname>
<given-names><![CDATA[WG]]></given-names>
</name>
</person-group>
<source><![CDATA[Curr HIV/AIDS Rep]]></source>
<year>2012</year>
<volume>9</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>218-22</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Bone loss in HIV : a contemporary review]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Co]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ar]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Ga]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Curr Opin Endocrinol Obes]]></source>
<year>2015</year>
<volume>22</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>446-51</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Bone alterations associated with HIV]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Warriner]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Mugavero]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Overton]]></surname>
<given-names><![CDATA[ET]]></given-names>
</name>
</person-group>
<source><![CDATA[Curr HIV/AIDS Rep]]></source>
<year>2014</year>
<volume>11</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>233-40</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Microbial translocation is a cause of systemic immune activation in chronic HIV infection]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brenchley]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Price]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Schacker]]></surname>
<given-names><![CDATA[TW]]></given-names>
</name>
<name>
<surname><![CDATA[Asher]]></surname>
<given-names><![CDATA[TE]]></given-names>
</name>
<name>
<surname><![CDATA[Silvestri]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Rao]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Nat Med]]></source>
<year>2006</year>
<volume>12</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1365-71</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jennifer Hoy]]></surname>
<given-names><![CDATA[Birgit Grund]]></given-names>
</name>
<name>
<surname><![CDATA[Mollie Roediger]]></surname>
<given-names><![CDATA[Kristine E. Ensrud]]></given-names>
</name>
<name>
<surname><![CDATA[Indira Brar R]]></surname>
<given-names><![CDATA[Colebunders]]></given-names>
</name>
<name>
<surname><![CDATA[Nathalie De Castro]]></surname>
<given-names><![CDATA[Margaret Johnson]]></given-names>
</name>
<name>
<surname><![CDATA[Anjali Sharma]]></surname>
<given-names><![CDATA[Andrew Carr]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: the SMART Body Composition Substudy]]></article-title>
<collab>Group TISBCS</collab>
<source><![CDATA[J Bone Min Res]]></source>
<year>2013</year>
<page-range>1-18</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Bone metabolism dysfunction mediated by the increase of proinflammatory cytokines in chronic HIV infection]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Menezes]]></surname>
<given-names><![CDATA[EGM de]]></given-names>
</name>
<name>
<surname><![CDATA[Machado]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Barbosa]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[de Paula]]></surname>
<given-names><![CDATA[FJA]]></given-names>
</name>
<name>
<surname><![CDATA[Navarro]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<source><![CDATA[J Bone Miner Metab]]></source>
<year>2017</year>
<volume>35</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>234-42</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Duvivier]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kolta]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Assoumou]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ghosn]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rozenberg]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Murphy]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
</person-group>
<source><![CDATA[AIDS]]></source>
<year>2009</year>
<volume>23</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>817-24</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Tenofovir-associated renal and bone toxicity]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Woodward]]></surname>
<given-names><![CDATA[CLN]]></given-names>
</name>
<name>
<surname><![CDATA[Hall]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[IG]]></given-names>
</name>
<name>
<surname><![CDATA[Madge]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Copas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Nair]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[HIV Med]]></source>
<year>2009</year>
<volume>10</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>482-7</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[TT]]></given-names>
</name>
<name>
<surname><![CDATA[Qaqish]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
</person-group>
<source><![CDATA[Aids]]></source>
<year>2006</year>
<volume>20</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>2165-74</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Bone disease in HIV infection: a practical review and recommendations for HIV care providers]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[McComsey]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Tebas]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2010</year>
<volume>51</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>937-46</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Bone Loss in the HIV-Infected Patient : Evidence, Clinical Implications , and Treatment Strategies]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[VW]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[TT]]></given-names>
</name>
</person-group>
<source><![CDATA[J Infect Dis]]></source>
<year>2012</year>
<volume>205</volume>
<numero>^s3</numero>
<issue>^s3</issue>
<supplement>3</supplement>
<page-range>391-8</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Interpretación de la densitometría ósea]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Río]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[JANO]]></source>
<year>2006</year>
<volume>1621</volume>
<page-range>71-3</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bonjoch]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Figueras]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Estany]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Perez-Alvarez]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Rosales]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[del Rio]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Aids]]></source>
<year>2010</year>
<volume>24</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>2827-33</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Prevalence and risk factors of low bone mineral density in Korean HIV-infected patients: impact of abacavir and zidovudine]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[H-S]]></given-names>
</name>
<name>
<surname><![CDATA[Chin]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
<name>
<surname><![CDATA[Shin]]></surname>
<given-names><![CDATA[H-S]]></given-names>
</name>
</person-group>
<source><![CDATA[J Korean Med Sci]]></source>
<year>2013</year>
<volume>28</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>827-32</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Prevalence of and risk factors for osteoporosis and fracture among a male HIV-infected population in the UK]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Short]]></surname>
<given-names><![CDATA[C-ES]]></given-names>
</name>
<name>
<surname><![CDATA[Shaw]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
<name>
<surname><![CDATA[Fisher]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Walker-Bone]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Gilleece]]></surname>
<given-names><![CDATA[YC]]></given-names>
</name>
</person-group>
<source><![CDATA[Int J STD AIDS]]></source>
<year>2014</year>
<volume>25</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>113-21</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Prevalence and risk factors of osteopenia/osteoporosis in Turkish HIV/AIDS patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aydin]]></surname>
<given-names><![CDATA[OA]]></given-names>
</name>
<name>
<surname><![CDATA[Karaosmanoglu]]></surname>
<given-names><![CDATA[HK]]></given-names>
</name>
<name>
<surname><![CDATA[Karahasanoglu]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Tahmaz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Nazlican]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<source><![CDATA[Brazilian J Infect Dis]]></source>
<year>2013</year>
<volume>17</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>707-11</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Tenofovir y su relación con osteoporosis en pacientes con VIH]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cruz rodriguez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Castro-DFranchis]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Reyes-Jimenez]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
</person-group>
<source><![CDATA[Med Int Mex]]></source>
<year>2015</year>
<volume>31</volume>
<page-range>150-4</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Tenofovir-associated bone density loss]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grigsby]]></surname>
<given-names><![CDATA[IF]]></given-names>
</name>
<name>
<surname><![CDATA[Pham]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Mansky]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Gopalakrishnan]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mansky]]></surname>
<given-names><![CDATA[KC]]></given-names>
</name>
</person-group>
<source><![CDATA[Ther Clin Risk Manag]]></source>
<year>2010</year>
<volume>6</volume>
<page-range>41-7</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Comparison of changes in bone density and turnover with abacavir- lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stellbrink]]></surname>
<given-names><![CDATA[H-J]]></given-names>
</name>
<name>
<surname><![CDATA[Orkin]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Arribas]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Compston]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gerstoft]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Van Wijngaerden]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2010</year>
<volume>51</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>963-72</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir- emtricitabine in antiretroviral-naive adults with HIV-1: A substudy of the NEAT001/ANRS143 randomised trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bernardino]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
<name>
<surname><![CDATA[Mocroft]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mallon]]></surname>
<given-names><![CDATA[PW]]></given-names>
</name>
<name>
<surname><![CDATA[Wallet]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gerstoft]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Russell]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Lancet HIV]]></source>
<year>2015</year>
<volume>2</volume>
<page-range>11</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Less Bone Loss with Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Taiwo]]></surname>
<given-names><![CDATA[BO]]></given-names>
</name>
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Fichtenbaum]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ribaudo]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Tsibris]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Klingman]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2015</year>
<volume>61</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1179-88</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tebas]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Hicks]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Granier]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Wynne]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Min]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[AIDS]]></source>
<year>2015</year>
<volume>29</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>2459-64</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[van Vonderen]]></surname>
<given-names><![CDATA[MG a]]></given-names>
</name>
<name>
<surname><![CDATA[Lips]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[van Agtmael]]></surname>
<given-names><![CDATA[M a]]></given-names>
</name>
<name>
<surname><![CDATA[Hassink E a]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Brinkman]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Geerlings]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<source><![CDATA[AIDS]]></source>
<year>2009</year>
<volume>23</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1367-76</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Improvement in renal function and bone mineral density after a switch from tenofovir/emtricitabine plus ritonavir/boosted protease inhibitor to raltegravir plus nevirapine: a pilot study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calza]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Magistrelli]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Colangeli]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Borderi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Conti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mancini]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Antivir Ther]]></source>
<year>2016</year>
<volume>21</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>217-24</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Osteoporosis and fracture risk associated with HIV infection and treatment]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Compston]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Endocrinol Metab Clin North Am]]></source>
<year>2014</year>
<volume>43</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>769-80</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Fractures after antiretroviral initiation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yin]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Kendall]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<source><![CDATA[AIDS (London, England)]]></source>
<year>2012</year>
<volume>26</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>2175-84</page-range></nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Low bone mass prevalence, therapy type, and clinical risk factors in an HIV-infected Brazilian population]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pinto Neto]]></surname>
<given-names><![CDATA[LF1]]></given-names>
</name>
<name>
<surname><![CDATA[Ragi-Eis]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Vieira]]></surname>
<given-names><![CDATA[NF]]></given-names>
</name>
<name>
<surname><![CDATA[Soprani]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Neves]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Ribeiro-Rodrigues R]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Densitom]]></source>
<year>2011</year>
<volume>1</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>434-9</page-range></nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="">
<collab>Ministerio de Salud</collab>
<source><![CDATA[Guía de práctica clínica (GPC) basada en la evidencia científica para la atención de la infección por VIH/Sida en adolescentes (con 13 años de edad o más) y adultos]]></source>
<year>2014</year>
<page-range>1-499</page-range></nlm-citation>
</ref>
<ref id="B34">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Management of Bone Mineral Density in HIV Infected Patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Negredo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bonjoch]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Clotet]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<source><![CDATA[Expert Opin Pharmacother]]></source>
<year>2016</year>
<volume>17</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>845-52</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
